The Minnesota Vikings recently received bad news regarding a J.J. McCarthy trade the potential haul that comes with it.

Strong demand for cancer drug Darzalex and psoriasis treatment Tremfya more ​than offset a steep falloff in ​sales of its ...

The drug and medical-device maker has been working to ensure consistent growth after losing patent protection for its ...

Stripping out certain one-time items, earnings are expected to come in at $2.68 a share, compared with $2.77 a share the prior year. REVENUE: The company is exp ...

Johnson & Johnson on Tuesday validated our decision to make it our newest Club stock, delivering a beat-and-raise quarter led ...

Johnson & Johnson reported first-quarter sales above Wall Street’s expectations and bumped up its outlook for the year, led ...

A Johnson & Johnson subsidiary filed for bankruptcy for a third time on Friday as the healthcare giant seeks to advance an approximately $8 billion proposed settlement that would end tens of thousands ...

Johnson & Johnson has informed the Health Resources and Services Administration (HRSA) that it has "no choice but to forgo implementation" of its controversial plan to swap out upfront 340B drug ...

Johnson & Johnson recently spun off its consumer health unit into a new company called Kenvue. The consumer health segment weighed on J&J's growth, but it could progress successfully as an independent ...

With an FDA review underway, Johnson & Johnson is aiming to “fundamentally change” how bladder cancer is treated. That’s how Biljana Naumovic, president of J&J’s U.S. solid tumor business, described ...